According to Draghici, the traditional method of measuring mRNA transcriptsanalyzing the differences in the levels that genes are expressedis not a comprehensive way to understand disease. "Our software takes those differences and tells us where along a pathway those genes went wrong," he explains.
Advaita's software has already garnered a Small Business Technology Transfer (STTR) Phase I and Phase II grant from the National Institutes of Health (NIH) worth $2.4M; and $125K from the Michigan Emerging Technologies Fund. In addition, Advaita was selected this year to participate in the prestigious NIH CAP (Commercialization Assistance Program).
While knowledge gained from grant-supported basic research frequently advances a particular field of science or engineering, clinically-relevant results show immediate potential for broader applicability and improved patient care. Such results may be translated through I-Corps into technologies with near-term benefits for the economy and society. With these goals in mind, Advaita plans to address the need for more streamlined drug-discovery methods that will save time and money for the academic and pharmaceutical industries. By leveraging Pathway-Guide's unique ability to more efficiently target specific genes implicated in a disease or disease treatment, the company will commercialize a technology benefitting both the Michigan economy and our society as a whole.
|Contact: Julie O'Connor|
Wayne State University - Office of the Vice President for Research